BRRGF:OTC-BerGenBio ASA (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 1.77

Change

0.00 (0.00)%

Market Cap

USD 0.21B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

BerGenBio ASA (BRRGF) Stock Analysis:
Based on the BerGenBio ASA stock forecasts from 0 analysts, the average analyst target price for BerGenBio ASA is not available over the next 12 months. BerGenBio ASA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BerGenBio ASA is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, BerGenBio ASA’s stock price was USD 1.77. BerGenBio ASA’s stock price has changed by +0.00% over the past week, -0.34% over the past month and -55.08% over the last year.

No recent analyst target price found for BerGenBio ASA
No recent average analyst rating found for BerGenBio ASA

About

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development i ...Read More

Company Website : https://www.bergenbio.com

Address : Jonas Lies vei 91, Bergen, Norway, 5009

Employees : 46

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.53

52 Week High : 4.00

52 Week Low : 1.77

200 Day Moving Average : 3.03

50 Day Moving Average : 2.08

Shares Held By Insiders : 34.43%

Shares Held by Institutions : 20.71%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

+0.51 (+0.52%)

 USD221.26B 31.83 4.06
CMXHF CSL Limited

-5.85 (-2.97%)

 USD96.21B 38.28 27.87
CSLLY CSL Limited

-0.30 (-0.31%)

 USD96.21B 38.30 27.87
WXIBF WuXi Biologics

-0.86 (-7.54%)

 USD50.58B 118.81 15.82
WXXWY WuXi Biologics (Cayman) Inc

-0.60 (-2.59%)

 USD50.52B 118.66 15.82
GNMSF Genmab A/S

-8.00 (-2.27%)

 USD23.15B 52.92 6.21
UCBJF UCB SA

N/A

 USD20.76B 19.85 15.20
UCBJY UCB SA

+1.21 (+2.40%)

 USD19.15B 18.25 15.20
SBHMY Sino Biopharmaceutical Limited

N/A

 USD14.87B 8.89 1.04
SBMFF Sino Biopharmaceutical Limited

+0.04 (+5.66%)

 USD14.87B 9.05 1.04

ETFs Containing BRRGF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.11% 22% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.11% 22% F 12% F
Trailing 12 Months  
Capital Gain -55.08% 35% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.08% 34% F 18% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 19.33% 46% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.33% 45% F 54% F
Risk Return Profile  
Volatility (Standard Deviation) 78.08% 50% F 38% F
Risk Adjusted Return 24.75% 48% F 43% F
Market Capitalization 0.21B 75% C 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.68 57% F 30% F
Price / Cash Flow Ratio -0.89 42% F 65% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -52.74% 52% F 17% F
Return on Invested Capital -58.67% 29% F 11% F
Return on Assets -30.43% 55% F 20% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.53 27% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector